| Literature DB >> 28744725 |
Jingtai Zhi1, Jingzhu Zhao1, Ming Gao2, Yi Pan3, Jianghua Wu3, Yigong Li1, Dapeng Li1, Yang Yu1, Xiangqian Zheng4.
Abstract
BACKGROUND: The incidence of papillary thyroid microcarcinoma (PTMC) has been increasing globally in the past few decades. PTMC does not have a distinctive morphology that results in differences in biological behavior. The aim of this study was to classify PTMCs according to the morphological features and explore the relationship with clinicopathological characteristics. Additionally, we sought to evaluate whether different variants of PTMC can be an independent predictor for lymph mode metastasis when considering other risk factors.Entities:
Keywords: Clinicopathological characteristics; Papillary thyroid microcarcinoma; Variant
Mesh:
Year: 2017 PMID: 28744725 PMCID: PMC5809566 DOI: 10.1007/s10147-017-1170-6
Source DB: PubMed Journal: Int J Clin Oncol ISSN: 1341-9625 Impact factor: 3.402
Fig. 1a Conventional variant: characterized by papillary architecture, Φ = 2 mm. b Follicular variant: a papillary carcinoma composed entirely or almost entirely of follicles, Φ = 3 mm. c Encapsulated variant: a papillary carcinoma totally surrounded by a capsule, Φ = 1 mm
Distribution of variants among 1041 patients between December 2014 and December 2015
| Subtype |
| Present |
|---|---|---|
| Conventional | 471 | 45.2 |
| Follicular | 454 | 43.6 |
| Encapsulated | 82 | 7.9 |
| Warthin-like | 17 | 1.6 |
| Solid | 3 | 0.3 |
| Oncocytic | 3 | 0.3 |
| Tall cell | 6 | 0.6 |
| Trabecular | 5 | 0.5 |
Clinicopathological characteristics of patients with three major variants of papillary thyroid microcarcinoma (PTMC)
| Characteristics |
| Present |
|---|---|---|
| Gender | ||
| Female | 800 | 79.4 |
| Male | 207 | 20.6 |
| Age (years) | 46 ± 9.5 | |
| ≥45 | 558 | 55.4 |
| <45 | 449 | 44.6 |
| Tumor size | 0.57 ± 0.18 | |
| >5 mm | 510 | 50.6 |
| ≤5 mm | 497 | 49.4 |
| Fibrosis | ||
| Absent | 15 | 1.5 |
| Present | 992 | 98.5 |
| Calcification | ||
| Absent | 688 | 68.3 |
| Present | 319 | 31.7 |
| Minimal ETE | ||
| Absent | 807 | 80.1 |
| Present | 200 | 19.9 |
| Vascular | 59 | 5.9 |
| Fat | 120 | 11.9 |
| Striated muscle | 8 | 0.8 |
| Nerve | 1 | 0.1 |
| Multiple MEE | 12 | 1.2 |
| Coexistence of HT | ||
| Absent | 742 | 73.7 |
| Present | 265 | 26.3 |
| Multifocality | ||
| Absent | 643 | 63.9 |
| Present | 364 | 36.1 |
| Lymph node metastases | ||
| Absent | 692 | 68.7 |
| Present | 315 | 31.3 |
| N-stage | ||
| N0 | 692 | 68.7 |
| N1a | 275 | 27.3 |
| N1b | 40 | 4.0 |
| Neck excision extent | ||
| Central | 953 | 94.6 |
| Central + lateral | 54 | 5.4 |
Minimal ETE minimal extrathyroidal extension, HT Hashimoto’s thyroiditis, LNM lymph node metastases
Comparison of the clinicopathological data among three variants of PTMC
| Characteristic | CPTMC | FPTMC | EnPTMC |
|
|
|---|---|---|---|---|---|
| Gender | |||||
| Female | 360 (76.4%) | 373 (82.2%) | 67 (81.7%) | 4.920 | 0.085 |
| Male | 111 (23.6%) | 81 (17.8%) | 15 (18.3%) | ||
| Age (years) | |||||
| ≥45 | 239 (50.7%) | 263 (57.9%) | 56 (68.3%) | 10.827 | 0.004 |
| <45 | 232 (49.3%) | 191 (42.1%) | 26 (31.7%) | ||
| Fibrosis | |||||
| Absent | 11 (2.3%) | 4 (0.9%) | 0 (0.0%) | 4.682 | 0.096 |
| Present | 460 (97.7%) | 450 (99.1%) | 82 (100%) | ||
| Calcification | |||||
| Absent | 351 (74.5%) | 308 (67.8%) | 29 (35.4%) | 49.564 | <0.001 |
| Present | 120 (25.5%) | 146 (32.2%) | 53 (64.6%) | ||
| Minimal ETE | |||||
| Absent | 370 (78.6%) | 355 (78.2%) | 82 (100%) | 22.143 | <0.001 |
| Present | 101 (21.4%) | 99 (21.8%) | 0 (0.0%) | ||
| Coexistence of HT | |||||
| Absent | 339 (72.0%) | 344 (75.8%) | 59 (72.0%) | 1.857 | 0.395 |
| Present | 132 (28.0%) | 110 (24.2%) | 23 (28.0%) | ||
| Multifocality | |||||
| Absent | 302 (64.1%) | 285 (62.8%) | 56 (68.3%) | 0.943 | 0.624 |
| Present | 169 (35.9%) | 169 (37.2%) | 26 (31.7%) | ||
| Tumor size | |||||
| >5 mm | 272 (57.7%) | 204 (44.9%) | 34 (41.5%) | 18.200 | <0.001 |
| ≤5 mm | 199 (42.3%) | 250(55.1%) | 48 (58.5%) | ||
| LNM | |||||
| Absent | 296 (62.8%) | 332 (73.1%) | 64 (78.0%) | 14.986 | 0.001 |
| Present | 175 (37.2%) | 122 (26.9%) | 18 (22.0%) | ||
CPTMC conventional variant PTMC, FPTMC follicular variant PTMC, EnPTMC encapsulated variant PTMC, minimal ETE minimal extrathyroidal extension, HT Hashimoto’s thyroiditis, LNM lymph node metastases
Pairwise comparison of clinicopathological features among three variants of PTMC
| Characteristic | CPTMC versus FPTMC | FPTMC versus EnPTMC | EnPTMC versus CPTMC |
|---|---|---|---|
| Age | 0.028 | 0.078 | 0.003 |
| Calcification | 0.025 | <0.001 | <0.001 |
| Minimal ETE | 0.894 | <0.001 | <0.001 |
| Tumor size | <0.001 | 0.560 | 0.006 |
| LNM | 0.001 | 0.351 | 0.008 |
CPTMC conventional variant PTMC, FPTMC follicular variant PTMC, EnPTMC encapsulated variant PTMC, minimal ETE minimal extra-thyroidal extension, HT Hashimoto’s thyroiditis, LNM lymph node metastases
Univariate analysis of lymph node metastasis and clinicopathological features in PTMC
| Characteristic | LNM− | LNM+ |
|
|
|---|---|---|---|---|
| Gender | ||||
| Female | 573 | 227 | 15.289 | <0.001 |
| Male | 119 | 88 | ||
| Age (years) | ||||
| ≥45 | 406 | 152 | 9.506 | 0.002 |
| <45 | 286 | 163 | ||
| Subtypes | ||||
| CPTMC | 296 | 175 | 14.986 | 0.001 |
| FPTMC | 332 | 122 | ||
| EnPTMC | 64 | 18 | ||
| Fibrosis | ||||
| Absent | 9 | 6 | 0.538 | 0.463 |
| Present | 683 | 309 | ||
| Calcification | ||||
| CPTMC | ||||
| Absent | 232 | 119 | 6.239 | 0.012 |
| Present | 64 | 56 | ||
| FPTMC | ||||
| Absent | 232 | 76 | 2.352 | 0.125 |
| Present | 100 | 46 | ||
| EnPTMC | ||||
| Absent | 24 | 5 | 0.581 | 0.446 |
| Present | 40 | 13 | ||
| Minimal ETE | ||||
| Absent | 585 | 222 | 26.890 | 0.000 |
| Present | 107 | 93 | ||
| Coexistence of HT | ||||
| Absent | 505 | 237 | 0.571 | 0.450 |
| Present | 187 | 78 | ||
| Multifocality | ||||
| Absent | 474 | 169 | 20.671 | 0.000 |
| Present | 218 | 146 | ||
| Tumor size | ||||
| >5 mm | 311 | 199 | 28.788 | 0.000 |
| ≤5 mm | 381 | 116 | ||
CPTMC conventional variant PTMC, FPTMC follicular variant PTMC, EnPTMC encapsulated variant PTMC, minimal ETE minimal extrathyroidal extension, HT Hashimoto’s thyroiditis, LNM lymph node metastases
Multivariate analysis of lymph node metastasis and clinicopathological features in PTMC
| Characteristics |
| SE | Wald |
| OR | 95% CI | |
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| Gender | 0.640 | 0.171 | 13.964 | 0.000 | 1.896 | 1.355 | 2.651 |
| Age | −0.331 | 0.143 | 5.381 | 0.020 | 1.393 | 1.053 | 1.842 |
| Subtypes | |||||||
| CPTMC | 8.681 | 0.013 | Reference | ||||
| FPTMC | −0.415 | 0.150 | 7.687 | 0.006 | 0.660 | 0.492 | 0.885 |
| EnPTMC | −0.469 | 0.296 | 2.522 | 0.112 | 0.625 | 0.350 | 1.116 |
| Tumor size | 0.426 | 0.155 | 7.527 | 0.06 | 1.530 | 1.129 | 2.074 |
| Fibrosis | −0.327 | 0.549 | 0.356 | 0.551 | 0.721 | 0.246 | 2.112 |
| Minimal ETE | 0.581 | 0.182 | 10.153 | 0.001 | 1.788 | 1.251 | 2.557 |
| Coexistence of HT | −0.060 | 0.166 | 0.130 | 0.719 | 0.942 | 0.680 | 1.305 |
| Multifocality | 0.537 | 0.147 | 13.282 | 0.000 | 1.712 | 1.282 | 2.285 |
| Constant | −1.400 | 0.644 | 4.725 | 0.030 | 0.247 | ||
CPTMC conventional variant PTMC, FPTMC follicular variant PTMC, EnPTMC encapsulated variant PTMC, minimal ETE minimal extrathyroidal extension, HT Hashimoto’s thyroiditis